NO20045249L - Epotilonderivat for behandling av hepatom og andre kreftsykdommer - Google Patents

Epotilonderivat for behandling av hepatom og andre kreftsykdommer

Info

Publication number
NO20045249L
NO20045249L NO20045249A NO20045249A NO20045249L NO 20045249 L NO20045249 L NO 20045249L NO 20045249 A NO20045249 A NO 20045249A NO 20045249 A NO20045249 A NO 20045249A NO 20045249 L NO20045249 L NO 20045249L
Authority
NO
Norway
Prior art keywords
treatment
progressing
radiotherapy
cancer
hepatoma
Prior art date
Application number
NO20045249A
Other languages
English (en)
Norwegian (no)
Inventor
John David Rothermel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20045249L publication Critical patent/NO20045249L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Silicon Polymers (AREA)
NO20045249A 2002-05-01 2004-11-30 Epotilonderivat for behandling av hepatom og andre kreftsykdommer NO20045249L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37706302P 2002-05-01 2002-05-01
PCT/EP2003/004581 WO2003092683A1 (en) 2002-05-01 2003-04-30 Epothilone derivative for the treatment of hepatoma and other cancer diseases

Publications (1)

Publication Number Publication Date
NO20045249L true NO20045249L (no) 2005-01-26

Family

ID=29401440

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045249A NO20045249L (no) 2002-05-01 2004-11-30 Epotilonderivat for behandling av hepatom og andre kreftsykdommer

Country Status (24)

Country Link
US (2) US20050282873A1 (ja)
EP (1) EP1503756B1 (ja)
JP (1) JP2005528414A (ja)
KR (1) KR20040106422A (ja)
CN (1) CN1649585A (ja)
AT (1) ATE439130T1 (ja)
AU (1) AU2003227702B2 (ja)
BR (1) BR0309711A (ja)
CA (1) CA2483826C (ja)
CY (1) CY1109607T1 (ja)
DE (1) DE60328772D1 (ja)
DK (1) DK1503756T3 (ja)
ES (1) ES2330324T3 (ja)
HK (1) HK1073601A1 (ja)
IL (1) IL164783A (ja)
MX (1) MXPA04010853A (ja)
NO (1) NO20045249L (ja)
NZ (1) NZ536178A (ja)
PL (1) PL211114B1 (ja)
PT (1) PT1503756E (ja)
RU (1) RU2358730C2 (ja)
SI (1) SI1503756T1 (ja)
WO (1) WO2003092683A1 (ja)
ZA (1) ZA200408492B (ja)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL211114B1 (pl) * 2002-05-01 2012-04-30 Novartis Ag Zastosowanie pochodnej epotilonowej w leczeniu choroby nowotworowej
CN1870995A (zh) * 2003-09-02 2006-11-29 诺瓦提斯公司 使用埃坡霉素的癌症治疗
US8394365B2 (en) 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
EP1640004A1 (en) * 2004-09-24 2006-03-29 Schering Aktiengesellschaft Use of epothilones in the treatment of bone metastases and bone tumors or cancers
WO2006055742A1 (en) * 2004-11-18 2006-05-26 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
AU2006336468B2 (en) 2005-02-11 2012-04-12 University Of Southern California Method of expressing proteins with disulfide bridges
US8008256B2 (en) 2006-05-01 2011-08-30 University Of Southern California Combination therapy for treatment of cancer
MX2008004267A (es) * 2008-03-28 2009-09-28 Posi Visionary Solutions Llp Metoclopramida de liberacion prolongada de 12 horas.
MX2008004268A (es) * 2008-03-28 2009-09-28 Posi Visionary Solutions Llp Metoclopramida de liberacion prolongada de 24 horas.
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
CN101747326B (zh) * 2010-01-12 2012-07-25 山东大学 18元大环内酯类埃博霉素化合物及其应用
CA2799202C (en) 2010-05-18 2016-07-05 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6660758B1 (en) * 1996-12-13 2003-12-09 The Scripps Research Institute Epothilone analogs
US6194181B1 (en) * 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
NZ513629A (en) * 1999-02-22 2004-01-30 Bristol Myers Squibb Co C-21 modified epothilones
GB9918429D0 (en) * 1999-08-04 1999-10-06 Novartis Ag Organic compounds
PL211114B1 (pl) * 2002-05-01 2012-04-30 Novartis Ag Zastosowanie pochodnej epotilonowej w leczeniu choroby nowotworowej

Also Published As

Publication number Publication date
KR20040106422A (ko) 2004-12-17
CY1109607T1 (el) 2014-08-13
HK1073601A1 (en) 2005-10-14
EP1503756A1 (en) 2005-02-09
ES2330324T3 (es) 2009-12-09
WO2003092683A1 (en) 2003-11-13
JP2005528414A (ja) 2005-09-22
AU2003227702A1 (en) 2003-11-17
PL211114B1 (pl) 2012-04-30
RU2358730C2 (ru) 2009-06-20
AU2003227702B2 (en) 2007-07-26
BR0309711A (pt) 2005-02-09
ZA200408492B (en) 2006-09-27
MXPA04010853A (es) 2005-02-14
RU2004135307A (ru) 2005-09-10
PT1503756E (pt) 2009-10-28
US20080161369A1 (en) 2008-07-03
EP1503756B1 (en) 2009-08-12
PL371727A1 (en) 2005-06-27
NZ536178A (en) 2007-10-26
SI1503756T1 (sl) 2010-01-29
CA2483826C (en) 2012-04-17
DE60328772D1 (de) 2009-09-24
CA2483826A1 (en) 2003-11-13
US20050282873A1 (en) 2005-12-22
IL164783A (en) 2011-08-31
IL164783A0 (en) 2005-12-18
CN1649585A (zh) 2005-08-03
DK1503756T3 (da) 2009-11-16
ATE439130T1 (de) 2009-08-15

Similar Documents

Publication Publication Date Title
HK1073601A1 (en) Epothilone derivative for the treatment of hepatoma and other cancer diseases
NO2017019I1 (no) Diarylhydantoinforbindelse, farmasøytisk sammensetning og anvendelse derav
EA201201154A1 (ru) Ингибиторы фосфатидилинозит-3-киназы и способы их применения
PH12019502586A1 (en) N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof
NZ580009A (en) Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
RU2014108042A (ru) Фармацевтическая композиция для лечения и профилактики злокачественной опухоли
MX2011012584A (es) Benzoxazepinas como inhibidores de pi3k/m tor, metodos para su uso y fabricación.
RU2012140185A (ru) Ингибирование ангиогенеза
EA201290062A1 (ru) Соединения, связывающие белки теплового шока, композиции и способы получения указанных соединений
EA200970317A1 (ru) Комбинированное лечение опухолей, экспрессирующих cd38
NO20044475L (no) 2-(2,6-diklorfenyl)-diarulimidazoler
RU2018102963A (ru) Производные анилинпиримидина и их применения
DE602005015304D1 (de) Krebstherapie mit einem nukleären rezeptorliganden und einem hdac-hemmer
WO2006031756A3 (en) Betulinol derivatives as anti-cancer agents
ATE461713T1 (de) Zusammensetzungen für die radioimmuntherapie von gehirn-tumoren
TW200732305A (en) Cancer chemotherapy
NO20055650D0 (no) Ruteinum (II)-komplekser for behandling av tumorer
EA200970949A1 (ru) Способы лечения неоплазии при помощи комбинации химиотерапевтических агентов и облучения
ATE406375T1 (de) Antitumor wirksame 2-substituierte d-homoestra-1, 3,5(10)-trien-3-yl sulfamate
WO2005048956A3 (en) Estradiol-related compounds and methods of use as anti-tumor agents

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application